Compare VRSK & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRSK | DXCM |
|---|---|---|
| Founded | 1971 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7B | 25.9B |
| IPO Year | 2009 | 2005 |
| Metric | VRSK | DXCM |
|---|---|---|
| Price | $220.36 | $70.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 22 |
| Target Price | ★ $278.73 | $86.41 |
| AVG Volume (30 Days) | 1.2M | ★ 4.8M |
| Earning Date | 02-25-2026 | 02-12-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | 2.02 | ★ 7.75 |
| EPS | ★ 6.54 | 1.80 |
| Revenue | $3,029,500,000.00 | ★ $4,515,900,000.00 |
| Revenue This Year | $8.62 | $17.41 |
| Revenue Next Year | $7.86 | $12.73 |
| P/E Ratio | ★ $33.68 | $38.70 |
| Revenue Growth | 7.30 | ★ 14.21 |
| 52 Week Low | $197.00 | $54.11 |
| 52 Week High | $322.92 | $93.25 |
| Indicator | VRSK | DXCM |
|---|---|---|
| Relative Strength Index (RSI) | 45.57 | 59.69 |
| Support Level | $220.31 | $65.60 |
| Resistance Level | $226.37 | $71.28 |
| Average True Range (ATR) | 4.11 | 2.33 |
| MACD | -0.14 | 0.04 |
| Stochastic Oscillator | 23.10 | 67.72 |
Verisk Analytics is a leading provider of data analytics and proprietary solutions supporting clients in the insurance ecosystem. Verisk operates under a single segment with two separate business units, underwriting and claims. Within underwriting, the company operates as both a statistical agent and advisory organization, collecting and aggregating industrywide claims and policy data and providing insurers with preapproved forms, rules, and loss costs. Aside from regulatory and compliance offerings, Verisk provides specialized solutions to power P&C underwriting and catastrophe risk assessment used in reinsurance and insurance-linked securities. Verisk's smaller claims business is critical in preventing fraud and estimating property insurance claims.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.